« Alzheimer's and Amyloid, Again |
| How Sleazy It Can Get »
July 27, 2010
Genzyme Telling Sanofi-Aventis to Buzz Off?
That's what Bloomberg is reporting. Meanwhile, the Wall Street Journal reported that GlaxoSmithKline has expressed interest in the recent past, and that J&J might get involved as well. If a deal goes through, no matter who ends up making it, it'll be a lot more expensive than it looked like being. But isn't that ever the way in M&A? The problem is, everyone except the buyer has a great interest in seeing things go off at the highest possible price.
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- Pay-to-Delay: Not Necessarily Illegal, But Not Long For The World
- GPCRs Are As Crazy As You Thought
- Aggravating Aggregators
- Making Changes Inside Merck's R&D
- One. . .Million. . .Pounds (For a New Antibiotic?)
- A Beta-Secretase Inhibitor Hits the Skids in Alzheimer's
- The Supreme Court Rules on Myriad
- Watching DNA Polymerase Do Its Thing